COMIRNATY 3 MCG / 0.3 ML
*SARSCOV2 S-PROTEIN MRNA, 5'[M27,3'-OGPPP(M12'-O)APG], 3'POLYA+LINKER : 3 MCG / 0.3 ML · DIN 02552078 · BIONTECH MANUFACTURING GMBH
Health Canada status: APPROVED
What is COMIRNATY?
COMIRNATY 3 MCG / 0.3 ML contains *SARSCOV2 S-PROTEIN MRNA, 5'[M27,3'-OGPPP(M12'-O)APG], 3'POLYA+LINKER : 3 MCG / 0.3 ML. It is listed in the Health Canada Drug Product Database under DIN 02552078, held by BIONTECH MANUFACTURING GMBH, supplied as SUSPENSION for INTRAMUSCULAR administration. Health Canada currently lists it as approved, status dated 24-Sep-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02552078 |
|---|---|
| Brand name | COMIRNATY |
| Generic / active ingredient | *SARSCOV2 S-PROTEIN MRNA, 5'[M27,3'-OGPPP(M12'-O)APG], 3'POLYA+LINKER : 3 MCG / 0.3 ML |
| Manufacturer | BIONTECH MANUFACTURING GMBH |
| Strength | 3 MCG / 0.3 ML |
| Dosage form | SUSPENSION |
| Route of administration | INTRAMUSCULAR |
| Schedule | Schedule D |
| ATC code | J07BN01 COVID-19, RNA-BASED VACCINE |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 24-Sep-2024 |
What can be used instead?
Other Canadian products sharing ATC code J07BN01 COVID-19, RNA-BASED VACCINE. 5 of 20 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| COMIRNATY | 10 MCG / 0.3 ML | SUSPENSION | BIONTECH MANUFACTURING GMBH | MARKETED | DIN 02541858 |
| COMIRNATY | 30 MCG / 0.3 ML | SUSPENSION | BIONTECH MANUFACTURING GMBH | MARKETED | DIN 02552035 |
| COMIRNATY | 30 MCG / 0.3 ML | SUSPENSION | BIONTECH MANUFACTURING GMBH | MARKETED | DIN 02541823 |
| SPIKEVAX | 0.1 MG | DISPERSION | MODERNA BIOPHARMA CANADA CORPORATION | MARKETED | DIN 02541270 |
| SPIKEVAX | 50 MCG / 0.5 ML | DISPERSION | MODERNA BIOPHARMA CANADA CORPORATION | MARKETED | DIN 02557770 |
| COMIRNATY | 10 MCG / 0.2 ML | SUSPENSION | BIONTECH MANUFACTURING GMBH | CANCELLED POST MARKET | DIN 02522454 |
| COMIRNATY | 3 MCG / 0.2 ML | SUSPENSION | BIONTECH MANUFACTURING GMBH | CANCELLED POST MARKET | DIN 02530325 |
| COMIRNATY | 30 MCG / 0.3 ML | SUSPENSION | BIONTECH MANUFACTURING GMBH | CANCELLED POST MARKET | DIN 02509210 |
| COMIRNATY | 30 MCG / 0.3 ML | SUSPENSION | BIONTECH MANUFACTURING GMBH | CANCELLED POST MARKET | DIN 02527863 |
| COMIRNATY OMICRON XBB.1.5 | 10 MCG / 0.2 ML | SUSPENSION | BIONTECH MANUFACTURING GMBH | CANCELLED PRE MARKET | DIN 02541831 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.